DOCSLIB.ORG

PERSONAL INFORMATION Francesco Rodeghiero WORK

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PERSONAL INFORMATION Francesco Rodeghiero WORK Curriculum Vitae PERSONAL INFORMATION Francesco Rodeghiero WORK EXPERIENCE February 2004- Present Scientific Director Fondazione Progetto Ematologia (Italy) August 2001-October 2015 Director of the Department of Cell Therapy and Hematology Azienda ULSS N.6 (Italy) <p>The Department includes a Unit for Bone Marrow Transplantation, a specialized Center for the diagnosis and treatment of Hemophilia and Thrombosis, and a Research Laboratory</p> 1989- 2016 Professor at the Postgraduate School of Hematology on a contract-basis University of Verona (Italy) February 1993-October 2015 Director of the Hematology Department Azienda ULSS N.6 (Italy) December 1985-October 2015 Director of the Hemostasis and Trombosis Center Azienda ULSS N.6 (Italy) September 2006-November 2016 Member; Chairman from June 2016 to November 2016 Ethics Committee on drugs research and investigational protocol studies of the Vicenza District (Italy) EDUCATION AND TRAINING July 1975- Degree in Medicine University School of Medicine (Italy) December 1984- Postgraduate specialization in Laboratory Medicine University of Padova (Italy) June 1981- Postgraduate specialization in Oncology University of Ferrara (Italy) July 1978- Postgraduate specialization in Hematology University of Ferrara (Italy) ADDITIONAL INFORMATION 15/12/2020 European Medicine Agency Page 1/46 Expertise He has been conducting clinical research in the fields of hematology and hemostasis since the early 1970s. His main interests include thrombocytopenia, hemophilia, von Willebrand disease, thrombophilia, acute promyelocytic leukemia, myeloma, policytemia vera, and the epidemiological aspects of haematological diseases. In the last decades he mainly devoted to clinical research in the field of ITP. Publications 1.T. Barbui, F. Rodeghiero, E. Dini The aspirin tolerance test in von Willebrands disease. Tromb Haemost 38(2): 510-513, 1977 2.F. Rodeghiero, T. Barbui Two dimensional immunoelectrophoresis of antithrombin III during disseminated intravascular coagulation in acute leukemia. Thromb Res 12(1): 191-196, 1977 3.T. Barbui, F. Rodeghiero, E. Dini, G. Mariani, M. L. Papa, R. De Biasi, R. Cordero-Murillo, C. Montero-Umana Subunits A and S inheritance in four families with congenital factor XIII deficiency. Br J Haematol 38(2): 267-271, 1978 4.F. Rodeghiero, T. Barbui Fibrin cross-linking in congenital factor XIII deficiency. J Clin Pathol 33(5): 434-437, 1980 5.F. Rodeghiero,T. Barbui, R. Battista, T. Chisesi, G. Rigoni, E. Dini Molecular subunits and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukemia. Thromb Haemost 43(1): 6-7, 1980 6.T. Barbui, F. Rodeghiero Hereditary dysfunctional antithrombin III (AT-III Vicenza). Thromb Haemost 45(1): 97, 1981 7.F. Rodeghiero, M. Morbin, T. Barbui Subnit A of factor XIII regulates subunit S plasma concentration. Thromb Haemost 46(3): 621-622, 1981 8.F. Rodeghiero, S. Castronovo, E. Dini Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired haemophilia. Thromb Haemost 48(3): 339-340, 1982 9.T. Barbui, R. Bassan, T. Chisesi, R. Battista, S. Cortelazzo, F. Rodeghiero, G. Capnist, P. Viero, A. D'Emilio, E. Dini Retrospective analysis of treatment of acute myeloblastic leukemia in patients more than 55 years old. Acta Haematol 67: 170-174, 1982 10.T. Barbui, F. Rodeghiero, S. Meli, E. Dini Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukemia during L-Asparaginase therapy. Acta Haematol 69(3): 188-191, 1983 15/12/2020 European Medicine Agency Page 2/46 11.T. Barbui, G. Finazzi, F. Rodeghiero, E. Dini Immunoelectrophoretic evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III Vicenza). Br J Haematol 54(4): 561-565, 1983 12.F. Rodeghiero, P. M. Mannucci, S. Viganò, T. Barbui, L. Gugliotta, M. Cortellaro, E. Dini Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 63(4): 965-969, 1984 13.F. Rodeghiero, T. Barbui, A. Dal Belin-Peruffo, E. Dini Defective fibrin crosslinking in acute leukemia. Thromb Haemost 52(3): 343-346, 1984 14.T. Barbui, R. Bassan, T. Chisesi, R. Battista, S. Cortellazzo, F. Rodeghiero, G. Capnist, A. DEmilio, P. Viero, E. Dini Treatment of acute lymphoblastic leukemia in adults. Hematol Oncol 3(1): 49-53, 1985 15.F. Rodeghiero, G. Castaman, T. Chisesi, A. De Rossi, A. Dalla Gassa, A. Del Mistro, E. Dini, S. Castronovo, E. Pornaro, L. Chieco Bianchi One year follow-up study of T-cell subsets and incidence of seropositivity for HTLV-I and HTLV-III antibodies in patients treated "on demand" or sporadically with clotting concentrates. Thromb Haemost 54(3): 665-668, 1985. 16.G. Castaman, F. Rodeghiero, G. F. Ronconi, E. Dini Successful treatment of neonatal "autoimmune" thrombocytopenia with high-doses intravenous immunoglobulins. Haematologica 70(3): 276-7, 1985 17.G. Ballerini, S. Guerra, F. Rodeghiero, G. Castaman A contribution to the pathology of acquired plasma factor XIII deficiency. Semin Thromb Hemost 11 (4): 357-61, 1985. 18.F. Rodeghiero, G. Castaman, L. Tonellato, E. Dini Erythrocyte fragmentation in disseminated intravascular coagulation (DIC) in acute leukaemia. Br J Haematol 61(3): 593-594, 1985 19.F. Rodeghiero Treatment of Hemophilia (editorial) Ric Clin Lab 15(4): 289-303, 1985. 20.P. M. Mannucci, M. Colombo, F. Rodeghiero Non A-, non B- hepatitis after factor VIII concentrate treated by heating and cloroform. Lancet 2(2): 1013, 1985. 21.R. Zanetti, P. M. Mannucci, E. Tanzi, A. G. Moroni, De Paschale, M. Morfini, V. Carnelli, M. C. Tirindelli, R. De Biasi, N. Ciavarella, V. De Rosa, F. Rodeghiero, M. Colombo Hepatitis B vaccination of 113 hemophiliacs: lower antibodies responses in anti-LAV/HTLV-III-positive patients. Am J Hematol 23: 339-345, 1986. 22.F. Rodeghiero, G. Castaman, E. Dini 15/12/2020 European Medicine Agency Page 3/46 Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69(2): 454-459, 1987. 23.F. Rodeghiero, G. Castaman, A. Dal Belin Peruffo, E. Dini, A. Galletti, E. Barone, G. Gastaldi Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation. Thromb Haemost 57(3): 252-258, 1987. 24.F. Rodeghiero, G. Castaman, E. Di Bona, M. Ruggeri, E. Dini Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case. Blut 5581): 45-48, 1987. 25.F. Rodeghiero, G. Castaman, G. Pesavento, F. Bonato, G. Muleo, C. Consarino Recurrent life-threatening epistaxis in a child with Bernard -Soulier syndrome controlled by bilateral ligation of external carotids and ethmoidal arteries. Acta Haematologica 77(3): 183-185, 1987. 26.F. Rodeghiero, G. Castaman Calibration of lyophilized standards for ristocetin cofactor activity of von Willebrand's factor (vWf) requires vWf -deficient plasma as diluent for dose-response curves. Thromb Haemost 58(4): 978-981, 1987 27.F. Rodeghiero, G. Castaman, E. Di Bona, M. Ruggeri, R. Lombardi, P. M. Mannucci Hyper-responsiveness to DDAVP for patients with with type I von Willebrand's disease and normal intra-platelet von Willebrand factor. Eur J Haematol 40(2): 163-167, 1988. 28.P. M. Mannucci, R. Lombardi, G. Castaman, J. Dent, A. Lattuada, F. Rodeghiero, T. S. Zimmerman Von Willebrand disease "Vicenza" with larger than normal ("super-normal") von Willebrand factor multimers in plasma. Blood 71 (1): 65-70, 1988. 29.F. Rodeghiero, G. Castaman, M. Vespignani, E. Dini, M. Bertazzoni Erythema multiforme after intravenous immunoglobulin. Blut 56(3): 145, 1988. 30.F. Rodeghiero, G. Castaman, R. Lombardi, P. M. Mannucci Von Willebrand factor abnormalities in two patients with uraemia. Lancet 2, 1016-1017, ottobre1988. 31.Gringeri, P. M. Mannucci and the Medical-Scientific Committee of the Fondazione dell'Emofilia (Milano). National Survey of human immunodeficiency virus infection in italian hemophiliacs: 1983-1987. Ric Clin Lab 18 (4): 275-280, 1988. 32.G. Castaman, F. Rodeghiero, E. Di Bona, M. Ruggeri Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy. Blut 58(4): 211-213, 1989 33.Tripodi, P. M. Mannucci and the ad hoc Study Group A survey of inherited thrombotic syndromes in Italy. Res Clin Lab 19(1): 67-74, 1989 15/12/2020 European Medicine Agency Page 4/46 34.G. Castaman, F. Rodeghiero, A. D'Emilio, E. Dini Juvenile essential thrombocythemia: really a benign disease? Haematologica 74(4): 416, 1989 35.G. Castaman, M. Ruggeri, F. Rodeghiero Increased proteolysis of antithrombin III Vicenza during disseminated intravascular coagulation in acute leukemia. Thromb Res 55: 661-664, 1989 36.F. Rodeghiero, G. Castaman, G. Soffiati, R. Quaglio, S. Castronovo, S. Cortesi, E. Dini Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukemia. Blut 59(2): 177-183, 1989 37.F. Rodeghiero, G. Castaman, A. Tosetto, E. Di Bona, M. Ruggeri Triton X present in platelet lysates critically affects von Willebrand factor ristocetin cofactor assay. Thromb Res 55: 521-526, 1989 38.F. Rodeghiero, G. Castaman, E. Di Bona, M. Ruggeri Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 74 (6): 1997-2000, 1989 39.P. M. Mannucci, A. Lattuada, G. Castaman, R. Lombardi, M. L. Colibretti, N. Ciavarella, F. Rodeghiero Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand's disease. Blood 74(7): 2433-2436, 1989 40.G. Castaman, M. Ruggeri, F. Rodeghiero A new Italian family with severe prekallikrein deficiency. DDAVP-induced fibrinolysis and coagulation changes in homozygous and heterozygous members. Ris Clin Lab 20 (4): 239-244, 1990 41.F. Rodeghiero, G. Castaman, E. Dini Fibrinopeptide A changes during remission induction treatment with l-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation.
Load more

Recommended publications
  • Recombinant Factors for Hemostasis
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Chemical & Biomolecular Engineering Theses, Chemical and Biomolecular Engineering, Dissertations, & Student Research Department of Summer 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra University of Nebraska at Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/chemengtheses Part of the Biochemical and Biomolecular Engineering Commons Calcaterra, Jennifer, "Recombinant Factors for Hemostasis" (2010). Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research. 5. https://digitalcommons.unl.edu/chemengtheses/5 This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Chemical & Biomolecular Engineering Theses, Dissertations, & Student Research by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Recombinant Factors for Hemostasis by Jennifer Calcaterra A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Interdepartmental Area of Engineering (Chemical & Biomolecular Engineering) Under the Supervision of Professor William H. Velander Lincoln, Nebraska August, 2010 Recombinant Factors for Hemostasis Jennifer Calcaterra, Ph.D. University of Nebraska, 2010 Adviser: William H. Velander Trauma deaths are a result of hemorrhage in 37% of civilians and 47% military personnel and are the primary cause of death for individuals under 44 years of age. Current techniques used to treat hemorrhage are inadequate for severe bleeding. Preliminary research indicates that fibrin sealants (FS) alone or in combination with a dressing may be more effective; however, it has not been economically feasible for widespread use because of prohibitive costs related to procuring the proteins.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb
    USOO6O19993A United States Patent (19) 11 Patent Number: 6,019,993 Bal (45) Date of Patent: Feb. 1, 2000 54) VIRUS-INACTIVATED 2-COMPONENT 56) References Cited FIBRIN GLUE FOREIGN PATENT DOCUMENTS 75 Inventor: Frederic Bal, Vienna, Austria O 116 263 1/1986 European Pat. Off.. O 339 607 4/1989 European Pat. Off.. 73 Assignee: Omrix Biopharmaceuticals S.A., O 534 178 3/1993 European Pat. Off.. Brussels, Belgium 2 201993 1/1972 Germany. 2 102 811 2/1983 United Kingdom. 21 Appl. No.: 08/530,167 PCTUS85O1695 9/1985 WIPO. PCTCH920.0036 2/1992 WIPO. 22 PCT Filed: Mar. 27, 1994 PCT/SE92/ 00441 6/1992 WIPO. 86 PCT No.: PCT/EP94/00966 PCTEP9301797 7/1993 WIPO. S371 Date: Nov.30, 1995 Primary Examiner-Carlos Azpuru Attorney, Agent, or Firm-Jacobson, Price, Holman, & S 102(e) Date: Nov.30, 1995 Stern, PLLC 87 PCT Pub. No.: WO94/22503 57 ABSTRACT PCT Pub. Date: Oct. 13, 1994 A two-component fibrin glue for human application includes 30 Foreign Application Priority Data a) a component A containing i) a virus-inactivated and concentrated cryoprecipitate that contains fibrinogen, and ii) Mar. 30, 1993 EP European Pat. Off. .............. 93105298 traneXamic acid or a pharmaceutically acceptable Salt, 51 Int. Cl." A61F 2/06; A61K 35/14 thereof, and b) component B containing a proteolytic 52 U s C - - - - - - - - - - - - - - - - - - - - - - - - - - -424/426. 530,380, 530/381: enzyme that, upon combination with component A, cleaves, O X O -- O - - - s 530(383. 530ass Specifically, fibrinogen present in the cryoprecipitate of 58) Field of Search 424/426,530,380 component A, thereby, effecting a fibrin polymer.
    [Show full text]
  • Comparison of Fibrin Adhesives Prepared by 3 Different Methods
    Original Article Int. Arch. Otorhinolaryngol. 2013;17(1):62-65. DOI: 10.7162/S1809-97772013000100011 Comparison of fibrin adhesives prepared by 3 different methods Juliana Benthien Cavichiolo1, Maurício Buschle2, Bettina Carvalho3. 1) Medical Resident in Otolaryngology, HC-UFPR (Hospital de Clínicas da Universidade Federal do Paraná). 2) MMSc. Physician Assistant, Department of Otolaryngology, Faculty of Medicine, UFPR; Associate Professor of Otolaryngology. 3) Otolaryngologist by ABORLCCF. Institution: Hospital de Clínicas da Universidade Federal do Paraná. Curitiba / PR - Brazil. Mailing address: Juliana Benthien Cavichiolo - Rua General Carneiro, 181 - Alto da XV - Curitiba / PR - Brazil - Zip code: 80060-900 - E-mail: [email protected] Article received on May 1, 2011. Article accepted on October 25, 2012. SUMMARY Introduction: Fibrin tissue adhesive, which has applications in several areas of medicine, can be prepared by different methods. Aim: To compare fibrin tissue adhesives prepared by 3 different methods. Method: In this prospective experimental laboratory study, fibrin tissue adhesives prepared by the use of plasma fibrinogen (group 1), cryoprecipitation (group 2), and precipitation by ammonium sulfate (group 3) were tested on 15 rabbits and 10 fragments of dura mater. The quality of the clots was assessed in terms of the success of the healing process, local toxicity, graft adhesion capacity, and degree of adhesion of 2 fragments of dura mater produced. Results: All methods produced a clot with high adhesion and no toxicity, but tensile strength testing revealed that the glue produced from the ammonium sulfate-precipitated clot (group 3) was the strongest, requiring 39 g/cm ² to separate the fragments as opposed to 23 g/cm ² for group 2 and 13 g/cm ² for group 1.
    [Show full text]
  • Does Tranexamic Acid Stabilised Fibrin Support the Osteogenic Differentiation of Human Periosteum Derived Cells? J
    JEuropean Demol et Cells al. and Materials Vol. 21 2011 (pages 272-285) DOI: 10.22203/eCM.v021a21 Fibrin for osteogenic differentiation ISSN of1473-2262 hPDCs? DOES TRANEXAMIC ACID STABILISED FIBRIN SUPPORT THE OSTEOGENIC DIFFERENTIATION OF HUMAN PERIOSTEUM DERIVED CELLS? J. Demol1,3, J. Eyckmans2,3, S.J. Roberts2,3, F.P. Luyten2,3 and H. Van Oosterwyck1,3,* 1 Division of Biomechanics and Engineering Design, 2 Laboratory for Skeletal Development and Joint Disorders, 3 Prometheus, Division of Skeletal Tissue Engineering Leuven, K.U. Leuven, Leuven, Belgium Abstract Introduction Fibrin sealants have long been used as carrier for osteogenic Fibrin is a natural polymer that is formed during blood cells in bone regeneration. However, it has not been clotting from its precursor protein fibrinogen. The demonstrated whether fibrin’s role is limited to delivering conversion of fibrinogen to fibrin is triggered by thrombin cells to the bone defect or whether fibrin enhances (Blomback, 1996). In fibrin sealants, this coagulation osteogenesis. This study investigated fibrin’s influence on process has been engineered into an adhesive system that the behaviour of human periosteum-derived cells (hPDCs) is widely used in many surgical fields to promote when cultured in vitro under osteogenic conditions in two- haemostasis, sealing and tissue bonding. Commercial dimensional (fibrin substrate) and three-dimensional (fibrin fibrin sealant kits contain highly purified and virally carrier) environments. Tranexamic acid (TEA) was used inactivated human fibrinogen and human thrombin to reduce fibrin degradation after investigating its effect (Jackson, 2001). Fibrin is a non-cytotoxic, fully on hPDCs in monolayer culture on plastic. TEA did not resorbable, bioactive matrix with multiple interaction sites affect proliferation nor calcium deposition of hPDCs under for cells and other proteins (Mosesson et al., 2001).
    [Show full text]
  • SAP American Society of Hematology Self-Assessment Program
    ASH®-SAP American Society of Hematology Self-Assessment Program SIXTH EDITION BK-ASH-SAP_6E-150511-FM.indd 1 4/29/2016 3:59:06 PM Disclosures As a provider accredited by the Accreditation Council for Hemostasis Research Society of North America (HTRS); Continuing Medical Education (ACCME), the American member of an advisory board for GlaxoSmithKline. Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational ac- Chapter 4, Hematopoietic growth factors tivities it sponsors. All authors are expected to disclose any financial relationships with any proprietary entity producing Aaron T. Gerds declares no competing financial interest. health care goods or services that have occurred within 24 Alan E. Lichtin declares no competing financial interest. months from the start of or during the production of the work and that are relevant to the author’s content. If an au- Chapter 5, Iron metabolism, iron overload, thor has such a financial interest, then she or he must dis- and the porphyrias close the name of the commercial interest and nature of the relationship (eg, consultant, grantee, etc.). An author who Heather A. Leitch has received honoraria, research funding, has no such financial relationship must declare that she or and/or served on advisory boards for Alexion, Apo-Pharma, he has nothing to disclose. The intent of this disclosure is Celgene, and Novartis. She is a member of the Exjade speak- not to prevent an author with a significant financial or other ers’ bureau. Jecko Thachil declares no competing financial relationship from making a presentation, but rather to pro- interest.
    [Show full text]
  • Engineered Technologies to Study the Role of Mechanical Signals in Human Lymphoma Growth and Therapeutic Response
    ENGINEERED TECHNOLOGIES TO STUDY THE ROLE OF MECHANICAL SIGNALS IN HUMAN LYMPHOMA GROWTH AND THERAPEUTIC RESPONSE A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Apoorva May 2018 © 2018 Apoorva ACKNOWLEDGEMENT I am very thankful to my advisor Ankur for his mentorship, support and constant encouragement. His passion and enthusiasm for research are contagious and inspiring. I appreciate his engaging, hands-on and proactive approach to research. I also appreciate Ankur’s patience, and how he went out of his ways to help me on several occasions-- Anything good I do, will be because of him. All this would not have been possible without Marcia Sawyer. Thank you to Marcia for all her unconditional support, encouragement and help. I am glad that when PhD gets tough, Marcia is around to talk to. Last but not least, I appreciate how she kept all the grad students informed and organized. For the phosphorylation studies, Prof. Cosgrove and Alex made significant contribution to the experiments and analysis. I am grateful to Prof. Cosgrove for inspiring discussions, feedback and access to his lab facility. For the computational analysis and microfluidic experiments, I often visited Prof. Kirby. I thank him for his time and ideas. I am also grateful to my other committee members, Prof. Archer and Prof. Shepherd, for their feedback and guidance. When I joined Singh lab, I had absolutely zero knowledge of biomedical engineering. Field and Alberto were the only students in the lab.
    [Show full text]
  • Hemostatic Agents in Hepatobiliary and Pancreas Surgery: a Review of the Literature and Critical Evaluation of a Novel Carrier-Bound Fibrin Sealant (Tachosil)
    International Scholarly Research Network ISRN Surgery Volume 2012, Article ID 729086, 12 pages doi:10.5402/2012/729086 Review Article Hemostatic Agents in Hepatobiliary and Pancreas Surgery: A Review of the Literature and Critical Evaluation of a Novel Carrier-Bound Fibrin Sealant (TachoSil) K. A. Simo,1 E. M. Hanna,1 D. K. Imagawa,2 and D. A. Iannitti1 1 Section of Hepatobiliary and Pancreas Surgery, Department of Surgery, Carolinas Medical Center, 1025 Morehead Medical Drive, Suite 300, Charlotte, NC 28204, USA 2 Division of Hepatobiliary and Pancreas Surgery and Islet Cell Transplantation, Department of Surgery, University of California, Irvine, Orange, CA 92868, USA Correspondence should be addressed to D. A. Iannitti, [email protected] Received 21 May 2012; Accepted 24 July 2012 Academic Editors: J.-M. Catheline, G. Nasso, and B. H. Yong Copyright © 2012 K. A. Simo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Despite progress in surgical techniques applied during hepatobiliary and pancreas (HPB) surgery, bleeding and bile leak remain significant contributors to postoperative mortality and morbidity. Topical hemostatics have been developed and utilized across surgical specialties, but data regarding effectiveness remains inconsistent and sparse in HPB surgery. Methods. A comprehensive search for studies and reviews on hemostatics in HPB surgery was performed via an October 2011 query of Medline, EMBASE, and Cochrane Library. In-depth evaluation of a novel carrier-bound fibrin sealant (TachoSil) was also performed. Results. The literature review illustrates multiple attempts have been made at developing different topical hemostatics and sealants to aid in surgical procedures.
    [Show full text]
  • Autologous Fibrin Glue: Automated Production and Adhesive Quality
    Current Directions in Biomedical Engineering 2017; 3(2): 397–400 Katharina Düregger*, Sabrina Frenzel and Markus Eblenkamp Autologous fibrin glue: automated production and adhesive quality Abstract: Fibrin glue is a two-component adhesive used to sealants offers the advantages of point of care preparation, stop bleeding, seal wound edges and for scaffolds in tissue reduced risk of contamination and immunological responses, engineering. Autologous products result in reduced risk of as well as economic factors when compared with contamination and immunological responses compared to commercially available, ready to use fibrin glues [2,4]. commercially available fibrin glue. However, reproducibility Disadvantages of patient derived fibrin glue preparations are due to patient dependent sealant properties of autologous found in low reproducibility due to variations between fibrin glue preparation is low. In this study a fully automated individuals [9]. production process for both the fibrinogen and thrombin The adhesive quality of fibrin glue correlates with the component from small blood volumes was developed. The polymerisation process of the fibrinogen-thrombin mixtures resulting fibrinogen concentration, thrombin activity and and depends on the thrombin activity and fibrinogen sealant properties of the fibrin glue were determined. The concentration [6]. In commercial sealants the thrombin fully automated and closed production system proved to be a activity has been reported at 4-1000 IU/ml [4,5] and the promising tool for fast and easy production of autologous fibrinogen concentration at 19.88 mg/ml, 35-55 mg/ml and fibrin glue with an effective adhesive quality. 80-100 mg/ml [4-6]. In autologous approaches the fibrinogen component is Keywords: Autologous fibrin glue, thrombin, fibrinogen, concentrated from whole blood with plasma fibrinogen levels automated production process, adhesive strength, adhesive of 2-6 mg/ml [9] of which up to 100 % can be recovered by quality, sealant properties, growth factors, autologous blood an optimized precipitation method [1].
    [Show full text]
  • Postoperative Pancreatic Fistula: a Review of Traditional and Emerging Concepts
    Journal name: Clinical and Experimental Gastroenterology Article Designation: REVIEW Year: 2018 Volume: 11 Clinical and Experimental Gastroenterology Dovepress Running head verso: Nahm et al Running head recto: Management of postoperative pancreatic fistula open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CEG.S120217 Open Access Full Text Article REVIEW Postoperative pancreatic fistula: a review of traditional and emerging concepts Christopher B Nahm1–3 Abstract: Postoperative pancreatic fistula (POPF) remains the major cause of morbidity after Saxon J Connor4 pancreatic resection, affecting up to 41% of cases. With the recent development of a consensus Jaswinder S Samra1,2,5 definition of POPF, there has been a large number of reports examining various risk factors, Anubhav Mittal1,2,5 prediction models, and mitigation strategies for this costly complication. Despite these strate- gies, the rates of POPF have not significantly diminished. Here, we review the literature and 1Upper Gastrointestinal Surgical Unit, Royal North Shore Hospital, Sydney, evidence regarding both traditional and emerging concepts in POPF prediction, prevention, and Australia; 2Northern Clinical School, management. In particular, we review the evidence for the association between postoperative Sydney Medical School, The University pancreatitis and POPF, and present a novel proposed mechanism for the development of POPF. of Sydney, Sydney, Australia; 3Bill Walsh Translational Cancer Research Keywords: postoperative pancreatic fistula,
    [Show full text]
  • Autologous Fibrinogen Purification and Concentration for Use in Fibrin Sealant
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2005-06-08 Autologous Fibrinogen Purification and Concentration For Use in Fibrin Sealant Steven M. Alston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Chemical Engineering Commons BYU ScholarsArchive Citation Alston, Steven M., "Autologous Fibrinogen Purification and Concentration For Use in Fibrin Sealant" (2005). Theses and Dissertations. 443. https://scholarsarchive.byu.edu/etd/443 This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. AUTOLOGOUS FIBRINOGEN PURIFICATION AND CONCENTRATION FOR USE IN FIBRIN SEALANT by Steven M. Alston, Jr. A dissertation submitted to the faculty of Brigham Young University in partial fulfillment of the requirements of the degree of Doctor of Philosophy Department of Chemical Engineering Brigham Young University August 2005 BRIGHAM YOUNG UNIVERSITY GRADUATE COMMITTEE APPROVAL of a dissertation submitted by Steven M. Alston, Jr. This dissertation has been read by each member of the following graduate committee and by majority vote has been found to be satisfactory. ___________________________ _____________________________________ Date Kenneth A. Solen, Chair ___________________________ _____________________________________ Date S.
    [Show full text]
  • Original Article Comparison of Efficacy and Safety of Fibrin Glue Versus
    Int J Clin Exp Med 2016;9(2):1236-1244 www.ijcem.com /ISSN:1940-5901/IJCEM0016937 Original Article Comparison of efficacy and safety of fibrin glue versus tranexamic acid for reducing blood loss in primary total knee arthroplasty: a systematic review and meta-analysis Jin Xu1*, Lei Wang2*, Xinlong Ma2 1Department of Anesthesia, Tianjin Hospital, Tianjin, China; 2Department of Orthopedics, Tianjin Hospital, Tianjin, China. *Equal contributors. Received September 26, 2015; Accepted January 21, 2016; Epub February 15, 2016; Published February 29, 2016 Abstract: Objective: A systematic review of randomized controlled trials (RCTs) and non-RCTs was performed to evaluate the efficacy and safety of reducing blood loss using fibrin glue and tranexamic acid in patients who un- derwent total knee arthroplasty (TKA). Method: Relevant randomized controlled trial (RCTs) and non-RCT literature dealing with fibrin glue and tranexamic acid in TKA for reducing total blood loss was collected and searched from Medline, Embase, Pubmed, and the Cochrane Library for publication dates up to September 2015. After testing for publication bias and heterogeneity across studies, data were aggregated for random-effects modeling when necessary. Results: Three RCTs and two non-RCTs were eligible for data extraction and thus were included for meta- analysis. Compared with fibrin sealant, intravenous tranexamic acid may be more effective in reducing the need for transfusion (RR 2.62, 95% CI 1.64 to 4.18, P<0.0001). There was no significant difference in the total blood loss (MD=273.30, 95% CI -129.70.70 to 672.30, P<0.00001), hemoglobin values (SMD -0.74, 95% CI -1.08 to -0.40, P<0.00001), thromboembolic events (RR 4.00, 95% CI 0.46 to 35.15), fever (RR 0.63, 95% CI 0.21 to 1.85), hematoma (RR 1.03, 95% CI 0.28 to 3.70) or infection (RR 0.46, 95% CI 0.11 to 2.03) when comparing the fibrin glue group and the tranexamic acid group.
    [Show full text]
  • Investor Meeting October 17-18, 2011 Barcelona
    Investor Meeting October 17-18,2011 Barcelona Monday, October 17th, 2011: Sant Cugat del Valles • A new era begins (Victor Grifols) 10:00 • Grifols Operational Framework (Victor Grifols) 10:15 • Integration Process Status (Thomas Glanzmann) 11:00 • Coffee Break 11:45 • Plasma Procurement Management (Shinji Wada) 12:15 • Lunch 13:15 • Capex (Mary Kuhn) 14:15 • Financials (Alfredo Arroyo) 15:00 • Q&A 16:00 • Transfer to Barcelona 2 Tuesday, October 18th, 2011: Parets del Valles • Global Commercial Area - Bioscience (Ramón Riera ) 09:00 - Sales & Marketing N.A. (Greg Rich ) 09:45 - Hospital and Diagnostic (Ramón Riera ) 10:30 • Coffee break 10:45 • R & D Review (Juan Ignacio Jorquera) 11:15 • Coffee Break 12:00 • Site visit 12:30 • Wrap-up (Victor Grifols) 13:30 • Lunch 14:00 • Transfer to Airport / Barcelona 3 Management Team Victor Grifols President & CEO Grifols, S.A. Thomas Glanzmann Chairman Board Grifols Inc. Shinji Wada President Plasma Centers Grifols Inc. Mary Kuhn President Manufacturing Operations Grifols Inc. Alfredo Arroyo CFO Grifols, S.A. Ramón Riera President Global Commercial Division Grifols, S.A. Greg Rich President & CEO Grifols Inc. Juan Ignacio Jorquera R & D Director Instituto Grifols, S.A. Juan I. Towse President Global Industrial Division Grifols, S.A. Nuria Pascual VP Director of Finance – Investor Relations Officer Grifols, S.A. 4 Disclaimer This document has been prepared by GRIFOLS, S.A. (GRIFOLS or the “Company”) exclusively for use during the Investor Day Presentation dated October 17 th -18 th , 2011. Therefore it cannot be disclosed or made public by any person or entity with an aim other than the one expressed above, without the prior written consent of the Company.
    [Show full text]